Forest's Celexa Adds Warning On Dose-Dependent QT Prolongation
This article was originally published in The Pink Sheet Daily
Executive Summary
The labeling revision, which reflects the results of a thorough QT study, makes Celexa the first drug in the SSRI/SNRI class of antidepressants to include a general warning about QT interval effects.